US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected
Executive Summary
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
You may also be interested in...
Postmarketing Trial For Horizon Thyroid Eye Drug Tepezza To Be Larger Than Expected
Horizon CEO says safety trial will be conducted in a larger patient population following discussions during the US FDA advisory committee meeting.
Keeping Track: Year-End Submissions Rush Brings Seven Novel Agents To US FDA
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
With Celgene Acquisition Closed, Bristol Faces Major Milestones
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
